|
| | SR0136 | | LRB103 31458 MST 59199 r |
|
|
| 1 | | SENATE RESOLUTION
|
| 2 | | WHEREAS, Respiratory Syncytial Virus disease (RSV) is a |
| 3 | | highly transmissible, seasonal virus that can have severe and |
| 4 | | unpredictable outcomes for infants, including hospitalization; |
| 5 | | and
|
| 6 | | WHEREAS, Nearly all children will be infected with RSV by |
| 7 | | age two, and most infants requiring hospitalization were |
| 8 | | previously healthy and born at term; and
|
| 9 | | WHEREAS, RSV is the leading cause of hospitalization among |
| 10 | | infants in the U.S.; and
|
| 11 | | WHEREAS, RSV is the most common cause of bronchiolitis |
| 12 | | (inflammation of the small airways in the lung) and pneumonia |
| 13 | | (infection of the lungs) in children younger than one year of |
| 14 | | age in the U.S.; and |
| 15 | | WHEREAS, The current RSV season has resulted in |
| 16 | | significant morbidity and increased mortality; and |
| 17 | | WHEREAS, In the U.S., RSV infections typically occur |
| 18 | | during late fall, winter, and early spring, which means urgent |
| 19 | | preparation is needed; and |
|
| | SR0136 | - 2 - | LRB103 31458 MST 59199 r |
|
|
| 1 | | WHEREAS, Monoclonal antibodies show promise in |
| 2 | | preventative protection against RSV; and |
| 3 | | WHEREAS, RSV disproportionally affects infants with |
| 4 | | Medicaid coverage, Native Americans, and Alaskan Natives; and
|
| 5 | | WHEREAS, The Vaccines For Children (VFC) program is a |
| 6 | | federally-funded program that provides vaccines at no cost to |
| 7 | | children who might not otherwise be vaccinated because of |
| 8 | | inability to pay; and
|
| 9 | | WHEREAS, VFC coverage is critical to ensure equity and |
| 10 | | access for all infants in order to have the greatest impact on |
| 11 | | disease burden; therefore, be it
|
| 12 | | RESOLVED, BY THE SENATE OF THE ONE HUNDRED THIRD GENERAL |
| 13 | | ASSEMBLY OF THE STATE OF ILLINOIS, that we urge the Centers for |
| 14 | | Disease Control and Prevention to include new RSV immunization |
| 15 | | technologies (including vaccines and monoclonal antibodies), |
| 16 | | within the federal VFC program if the Advisory Committee on |
| 17 | | Immunization Practices of the Centers for Disease Control and |
| 18 | | Prevention issues administrative recommendations that are |
| 19 | | subsequently approved by the Director of the Centers for |
| 20 | | Disease Control and Prevention; and be it further
|
| 21 | | RESOLVED, That suitable copies of this resolution be |